X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12840) 12840
Book Review (2372) 2372
Publication (1228) 1228
Book Chapter (37) 37
Conference Proceeding (25) 25
Dissertation (9) 9
Magazine Article (9) 9
Trade Publication Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
Newspaper Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (10869) 10869
index medicus (10656) 10656
humans (10288) 10288
female (6419) 6419
male (5484) 5484
oncology (5135) 5135
middle aged (4812) 4812
aged (4575) 4575
adult (3220) 3220
treatment outcome (3220) 3220
ophthalmology (3179) 3179
chemotherapy (3135) 3135
cancer (3037) 3037
antineoplastic combined chemotherapy protocols - therapeutic use (2973) 2973
angiogenesis inhibitors - administration & dosage (2923) 2923
antibodies, monoclonal, humanized (2765) 2765
endothelial growth-factor (2568) 2568
vascular endothelial growth factor a - antagonists & inhibitors (2411) 2411
vascular endothelial growth factor (2348) 2348
angiogenesis inhibitors - therapeutic use (2322) 2322
antibodies, monoclonal - administration & dosage (2094) 2094
antibodies, monoclonal, humanized - administration & dosage (2040) 2040
aged, 80 and over (2027) 2027
care and treatment (2013) 2013
angiogenesis (1984) 1984
intravitreal injections (1766) 1766
retrospective studies (1688) 1688
therapy (1658) 1658
ranibizumab (1651) 1651
animals (1574) 1574
medicine & public health (1478) 1478
metastasis (1455) 1455
macular degeneration (1434) 1434
research (1362) 1362
colorectal neoplasms - drug therapy (1338) 1338
colorectal cancer (1314) 1314
drug therapy (1312) 1312
follow-up studies (1311) 1311
disease-free survival (1294) 1294
bevacizumab - administration & dosage (1287) 1287
antibodies, monoclonal - therapeutic use (1227) 1227
pharmacology & pharmacy (1205) 1205
antineoplastic combined chemotherapy protocols - adverse effects (1145) 1145
angiogenesis inhibitors (1136) 1136
angiogenesis inhibitors - adverse effects (1133) 1133
trial (1128) 1128
analysis (1105) 1105
survival (1080) 1080
vegf (1068) 1068
tomography, optical coherence (1042) 1042
clinical trials (1016) 1016
colorectal neoplasms - pathology (1008) 1008
antibodies, monoclonal, humanized - therapeutic use (1002) 1002
antineoplastic agents - therapeutic use (1000) 1000
antineoplastic agents (962) 962
fluorouracil - administration & dosage (960) 960
surgery (957) 957
tumors (949) 949
antineoplastic combined chemotherapy protocols - administration & dosage (944) 944
prospective studies (935) 935
prognosis (930) 930
antimitotic agents (929) 929
patients (916) 916
hematology, oncology and palliative medicine (913) 913
eye diseases (883) 883
lung neoplasms - drug therapy (882) 882
combination (846) 846
fluorescein angiography (844) 844
fluorouracil (834) 834
visual acuity (829) 829
neoplasm staging (814) 814
antibodies, monoclonal - adverse effects (798) 798
health aspects (794) 794
oxaliplatin (791) 791
neoplasm metastasis (786) 786
paclitaxel (772) 772
avastin (764) 764
camptothecin - analogs & derivatives (758) 758
neovascularization (747) 747
cancer therapies (730) 730
antibodies, monoclonal, humanized - adverse effects (728) 728
organoplatinum compounds - administration & dosage (723) 723
cetuximab (705) 705
1st-line treatment (704) 704
leucovorin (704) 704
phase-ii trial (696) 696
mice (694) 694
genetic structures (692) 692
irinotecan (690) 690
phase-iii trial (685) 685
abridged index medicus (677) 677
intravitreal bevacizumab (677) 677
carcinoma, non-small-cell lung - drug therapy (675) 675
injections (674) 674
combined modality therapy (672) 672
survival rate (662) 662
time factors (662) 662
drug administration schedule (652) 652
studies (646) 646
choroidal neovascularization - drug therapy (635) 635
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12148) 12148
Japanese (241) 241
German (168) 168
French (147) 147
Spanish (46) 46
Chinese (27) 27
Korean (20) 20
Polish (16) 16
Hungarian (13) 13
Russian (11) 11
Czech (9) 9
Romanian (9) 9
Italian (7) 7
Finnish (3) 3
Swedish (3) 3
Portuguese (2) 2
Hebrew (1) 1
Icelandic (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 3, pp. 411 - 419
Toxicities associated with vascular endothelial growth factor–targeted therapies can often compromise clinical benefit in patients with metastatic renal cell... 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | toxicity | renal cell carcinoma | risk factors | treatment discontinuation | model | VEGF‐targeted therapies | VEGF-targeted therapies | SAFETY | OLDER-ADULTS | PHASE-III | SORAFENIB | CANCER | INTERFERON-ALPHA | ANGIOGENESIS INHIBITOR THERAPIES | ONCOLOGY | TREATMENT PATTERNS | SUNITINIB | CLINICAL-PRACTICE | Predictive Value of Tests | Humans | Middle Aged | Male | Fatigue - chemically induced | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Indoles - administration & dosage | Kidney Neoplasms - blood | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Bevacizumab - administration & dosage | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Niacinamide - adverse effects | Mucositis - chemically induced | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Indazoles - adverse effects | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Bevacizumab - adverse effects | Imidazoles - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Retrospective Studies | Vascular Endothelial Growth Factor A - drug effects | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Databases, Factual | Molecular Targeted Therapy - adverse effects | Carcinoma, Renal Cell - blood | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Models, Statistical | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Care and treatment | Dosage and administration | Carcinoma, Renal cell | Diagnosis | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 21, pp. 2240 - 2247
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3347 - 3353
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1278 - 1286
Journal Article
Cancer, ISSN 0008-543X, 10/2011, Volume 117, Issue 20, pp. 4617 - 4622
BACKGROUND: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC) usually have a short survival. The chemotherapy combination of cisplatin... 
second‐line and temozolomide | chemotherapy | neuroendocrine cancer | PDEC | second-line and temozolomide | TRACT | PHASE-II TRIAL | ETOPOSIDE | NEUROENDOCRINE TUMORS | CISPLATIN | ONCOLOGY | SMALL-CELL CARCINOMA | Capecitabine | Humans | Middle Aged | DNA Repair Enzymes - genetics | Male | Antineoplastic Agents, Alkylating - administration & dosage | DNA Repair - genetics | Promoter Regions, Genetic - genetics | Bevacizumab | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Adult | Female | Carcinoma, Neuroendocrine - chemistry | Retrospective Studies | Dacarbazine - administration & dosage | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Neuroendocrine - genetics | Etoposide - administration & dosage | Treatment Outcome | DNA Methylation - genetics | Disease Progression | Disease-Free Survival | DNA Modification Methylases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Aged | Deoxycytidine - analogs & derivatives | Salvage Therapy - methods | Endocrine gland cancer | Care and treatment | Dosage and administration | Temozolomide | Research | Carcinoma | Medical treatment | Medical services | Etoposide | Patients | Survival | Cisplatin | Metastases | Chemotherapy | Methylation | Cancer | Index Medicus | Abridged Index Medicus | temozolomide | second-line | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 310 - 320
The addition of bevacizumab to neoadjuvant combination chemotherapy significantly increased the percentage of patients with a pathological complete response.... 
PROJECT PROTOCOL B-27 | TRIAL | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | THERAPY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | PHASE-III | DISEASE | DOCETAXEL | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Angiogenesis Inhibitors - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Logistic Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 | Deoxycytidine - analogs & derivatives | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Heart | Mucositis | Gemcitabine | Review boards | Body weight | Cancer therapies | Antimetabolites | Doxorubicin | ErbB-2 protein | Patients | Feet | Metastases | Cyclophosphamide | Epidermal growth factor | Ventricle | Taxanes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 1, pp. 13 - 21
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article